HUTCHMED will take a broad slate of oncology data to ESMO 2025, headlined by the FRUSICA-2 registration study of fruquintinib plus sintilimab as second-line therapy in locally advanced or metastatic renal cell carcinoma, a Mini Oral that will anchor the company’s presence in Berlin. The company will also field further analyses from FRUSICA-1 in endometrial cancer, multiple fruquintinib studies in metastatic colorectal cancer, including a global expanded access program, radiomics-based biomarker work, and a pooled safety analysis. On the lung front, savolitinib updates from the SACHI and SAVANNAH programs will examine MET-driven resistance after EGFR TKI therapy, alongside real-world testing and ctDNA insights. Investigator-initiated studies extend the footprint of surufatinib across periampullary carcinoma, NSCLC, pancreatic cancer, and sarcoma.
This package reads as a deliberate attempt to reposition a China-discovered portfolio as a combination of backbones in globally relevant settings. The strategic question is whether a China-first combo architecture—pairing fruquintinib with domestic PD-1s and pairing savolitinib with osimertinib—can convert into label-expanding, payer-acceptable standards of care beyond China through partners like Takeda and AstraZeneca.
For RCC, the comparator set in FRUSICA-2—axitinib or everolimus—targets a second-line space that remains unsettled in the immunotherapy era. If the fruquintinib plus sintilimab data show clinically meaningful benefit with a manageable toxicity burden, it could reshape China’s 2L algorithms and pressure incumbents on price and access, especially where domestic PD-1s have shifted cost dynamics. Ex-China, the PD-1 backbone matters: using sintilimab may limit immediate global portability, but positive efficacy could justify fast-follow trials with Western checkpoint backbones and give Takeda a rationale to pursue RCC beyond fruquintinib’s established mCRC label.
In endometrial cancer, analyses from FRUSICA-1 in pMMR disease align with the class precedent set by lenvatinib plus pembrolizumab. Here, the opportunity is twofold: create a cost-competitive alternative in China and parts of Asia, and test whether distinct safety and metabolic profiles enable better tolerability in a population prone to hypertension, diabetes, and obesity. The metabolic syndrome readout is a practical lever for Medical Affairs to guide patient selection and manage adverse events, and for payers to assess the real-world durability of therapy.
Savolitinib’s ESMO presence targets a different friction point: operationalizing MET testing and treatment sequencing after first-line osimertinib in EGFR-mutant NSCLC. ctDNA analyses and real-world data on MET amplification and overexpression thresholds could lower adoption barriers, but the competitive bar is high. Amivantamab-based regimens and other MET inhibitors are vying for the same post-osimertinib niche, and clarity on diagnostic cut-offs and timing will be decisive for guidelines, prior authorization criteria, and path lab readiness.
The fruquintinib expanded access, pooled safety, and AI radiomics biomarker work speak directly to payer and HTA evidence needs amid a crowded anti-angiogenic class. If the imaging biomarker reliably enriches for benefit, it could evolve into a differentiating companion tool, though regulatory acceptance of radiomics remains nascent and will demand prospective validation. Meanwhile, the surufatinib investigator-initiated studies suggest a search for new footholds after mixed ex-China regulatory progress; absent randomized data, these are more likely to shape hypothesis generation and local practice than near-term labels.
What to watch now is signal strength and translatability: the magnitude of benefit and tolerability in FRUSICA-2 relative to entrenched RCC options, whether savolitinib readouts tighten the MET testing algorithm enough to influence guidelines, and whether partners commit to global expansion programs with Western backbones. The next 12 months will test if HUTCHMED’s China-first combination strategy can scale into globally competitive labels—or remain a regionally advantaged play.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
